Oncovista Innovative Therapies Inc · OTC:OVIT
Oncovista Innovative Therapies — Investor Presentation (March 2008)
28 slides from Oncovista Innovative Therapies's investor presentation, Mar 6, 2008
Slide 1: OncoVista Innovative Therapies
OncoVisTa” INNOVATIVE THERAPIES = OTC BB: OVIT.OB
Slide 2: Safe Harbor Statement
oncoVista’ INNOVATIVE THERAPIES = Safe Harbor Statement Certain matters discussed in this presentation are “forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the ‘Company's statement
Slide 3: Who are we? Pipeline and strategy? What makes us different?
INNOVATIVE THERAPIES oncoVista’ q » Who are we? . y 4 What is our pipeline and drug development stra’ What makes us different?
Slide 4: Mission Statement
oncoVisTa’ Mission Statement OncoVista is a bio-pharmaceutical company dedicated to providing safe, efficacious and targeted treatments for cancer through the use of biomarkers in order to extend and improve the quality of life for patients.
Slide 5: Corporate Landmarks
oncoVisTa’ Corporate Landmarks Company Founded based on two key platform technologies Acquired majority share in AdnaGen AG Merged with Aengus Pharmaceuticals Acquired a Phase I/II clinical candidate Became publicly-traded In-licensed a Phase II clinical candidate Acquired controlling interest in Ad
Slide 6: Cancer Facts
oncoVisT= = Cancer Facts @ Cancer is the second leading U.S. cause of death* @ 1 death from cancer every minute ® $78.2 billion expenditures for cancer** “American Cancer Society “In 2006 U.S. health care ‘Source: National institutes of Health 4
Slide 7: What makes us different?
What makes us different?
Slide 8: What Makes Us Different?
oncoVisTa’ What Makes Us Different? e e People: @ An experienced management team with a proven track of drug approvals Innovative Molecules: @ Abalanced portfolio of proprietary clinical drug candidates Integration of Diagnostics in Clinical Drug Development: @ Circulating Tumor Cells (CTCs) are bio
Slide 9: Management Team
oncoW sta Management Team Alexander L. Weis, Ph.D. J. Michael Edwards, M.B.A. Corey Levenson, Ph.D. Chairman, CEO & President Chief Financial Officer Chief Technical Officer + Co-founder of ILEX Oncology + PricewaterhouseCoopers, US Global = ILEX Oncology, + Founder of Lipitek, worked with Investors
Slide 10: Management Team
oncoVisTa’ INNOVATIVE THERAPIES Management Team Michael Moloney, M.B.A. Director of Program Management + CALGB, Duke University, BioNumerik Pharmaceuticals + 20+ years experience in drug development and IT J. Kay Noel, Ph.D. Director of Regulatory Affairs + Axiom Pharmaceuticals, Cetus Corporation,
Slide 11: Clinical Advisory Board
oncoVista’ Clinical Advisory Board Eric Rowinsky, M.D. Ronald P. McCaffrey, M.D. Pedro Santabarbara, Senior VP and Chief Medical Harvard Medical Schoo! M.D., Ph.D. Officer ImClone Systems, Inc:) Massachusetts General Hosptal VP Strategic Development and Key role in development of: Medical Afar (PHAR
Slide 12: Current Cancer Chemotherapy
oncoVisTa” Current Cancer Chemotherapy a Be ) r=] SS @ Efficacy is Low @ Therapies are toxic and non-specific @ Measures of Response are Inadequate @ Based on tumor size @ There is a High Failure Rate @ Responses are not durable 12
Slide 13: Our Unique Approach
onco\isTa” Our Unique Approach ] ®@ Identify biomarkers that are associated with specific cancer types @ Target treatments selectively to cancer cells based on biomarker expression @ Identify and treat only patients who express the biomarkers and are therefore most likely to benefit from treatment @
Slide 14: Our Product Pipeline
Our Product Pipeline AdnaGen Diagnostics* OVI-237 OVI-423 (Cordycepin) Ovi-t17 (L-Nucleoside conjugate) Tubulin-Isotype Specific Anti-Mitotics *cu ket ly —— —— —— = — ==
Slide 15: IP Summary
oncoVista’ e IP Summary We are aggressively pursuing protection of our intellectual property through application for, and maintenance of, US and International patents 22 issued US and Worldwide patents Over two dozen applications on file 15
Slide 16: AdnaGen Diagnostics
oncoVista AdnaGen Diagnostics - Kits for five indications - Revenues from sales in Europe icl-0 J ours fi collection to detection Collected blood Capture of tumor _Lysis of captured Amplification of Detection of from patient cells using ‘tumor cells to biomarker tumor associated antib on release con
Slide 17: Use of CTCs in Cancer Drug Development
oncoVista’ Use of CTCs in Cancer Drug Development e CTCs provide insight into metastatic disease target e Our technology for capture and detection of CTCs is superior to +f competing methods @ Use of CTCs will lead to @ Rapid determination of whether a particular treatment is helping a patient @ Les
Slide 18: Advantages of Our Drug Development Strategy
oncoVista’ Advantages of Our Drug Development Strategy Increased response rates and lower toxicities of drugs More rapid and less costly path to marketing approval Biomarkers can be used for detection of disease and monitoring of treatment CTCs provide insight into which drugs will be effective agai
Slide 19: OVI-237 (Liposomal TS Inhibitor)
oncoVisTa OVI-237 (Liposomal TS Inhibitor) ° «eee An advanced Phase II clinical-stage drug Activity seen in breast and gastric cancer patients Status: Phase Ill clinical trial program being planned IP: Patent protection through 2021 Development / Registration Plan: Significantly increase likelihood
Slide 20: OVI-123 (Cordycepin)
oncoVisTa’ 4 OVI-123 (Cordycepin) @ A Phase I/II clinical-stage drug ® Active against TdT-positive leukemias @ IP: Patent protection through 2014 Next generation analogs: 2023 @ Status: Phase I/II clinical trial at two sites Orphan Drug Designation obtained © Relevant Biomarker: TdT Market Potential
Slide 21: OVI-117 (L-Nucleoside Conjugate)
oncoVista’ OVI-117 (L-Nucleoside Conjugate) e « «#¢eeee Late preclinical stage drug Active in vivo: Colon, breast and prostate cancer models, with reduced toxicity Status: Currently in GLP animal drug safety studies IP: Patent protection through 2019 Development Plan: Complete GLP toxicology studies
Slide 22: Tubulin-Isotype Specific Anti-Mitotics
oncoVisTa Tubulin-lsotype Specific Anti-Mitotics ® Preclinical stage development program — molecular modeling, synthesis and biochemical screening ® Tubulin isotype selectivity seen in binding assays 7 Status: Lead evaluation and selection is on-going € IP: Multiple US and international patent appli
Slide 23: Key Projected Milestones
oncoVista’ Key Projected Milestones ® Submit IND for OVI-117 Phase | Trial ~ @ Commence OVI-237 Phase Il for Metastatic Breast Cancer ® Acquire next Phase Il in-license ————_——=aid) @ Interim assessment for OVI-123 Phase I/II trial in Leukemia @ ~~ Receive FDA approval for _ Metastatic Breast CTC te
Slide 24: Financing History
oncoVisTta’ 2004 2005 2006 2007 Financing History $0.6 million start-up financing - Round A $4.4 million - Round B1 $1.9 million - Round B2 $6.8 million - Round C 24
Slide 25: Business Portfolio
oncoVisTa” Business Portfolio — Portfolio: ‘compounds and etnolgies wh sigiscnt Potenia forxgeted otecve, sae retort Clinical Development: "e9iaton-d ‘asad on Oresson mn CTs tunity: ‘esate tectnciogy applicable to many cancers Pipeline Strategy Focus: tegeted cancer eaten and biomarkers Market Poten
Slide 26: Our Strategy for Creating Value
oncoVisTa’ Our Strategy for Creating Value ® Develop and grow the market for AdnaGen diagnostic kits to build near-term revenues @ Utilize our capabilities to cost effectively develop drugs that have previously shown activity in cancer patients, albeit at a level which was not adequate to gain marke
Slide 27: Our Keys to Success
oncoVisTa” Our Keys to Success e Proven management and advisory board track record Innovative molecules for cancer therapy A unique and proprietary approach for developing drugs based upon biomarkers in CTCs A focus on targeted treatment of metastatic disease a7
Slide 28: OncoVista, Inc. contact details
fii f oncow San OncoVista, Inc. 14785 Omicron Drive, Suite 104 San Antonio, TX 78245-3222 http://www.oncovista.com
Oncovista Innovative Therapies — Investor Presentation (March 2008) on 6ix